Aardvark Therapeutics to Present at Upcoming Investor Conferences in December

Rhea-AI Summary

Aardvark Therapeutics (Nasdaq: AARD) will present at two investor conferences in December: Piper Sandler 37th Annual Healthcare Conference in New York on Wednesday, December 3, 2025 at 8:00 a.m. ET and Evercore ISI 8th Annual Healthcare Conference in Miami on Thursday, December 4, 2025 at 11:15 a.m. ET.

Live webcasts of each presentation will be accessible on the company investor website and an archived recording will be available there for approximately one month after each presentation.

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the following conferences during December:

• Piper Sandler 37^th Annual Healthcare Conference in New York
  Presentation: Wednesday, December 3 at 8:00 a.m. ET
  
  
• Evercore ISI 8^th Annual Healthcare Conference in Miami
  Presentation: Thursday, December 4 at 11:15 a.m. ET
  
  

Live webcasts of each presentation will be accessible on the company’s website, www.aardvarktherapeutics.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.

About Aardvark Therapeutics, Inc.
Aardvark is a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of PWS and metabolic diseases. Recognizing hunger (the discomfort from not having eaten recently) is a distinct neural signaling pathway separate from appetite (the reward-seeking, desirability of food). Our programs explore therapeutic applications in hunger associated indications and potential complementary uses with anti-appetite therapies. Our lead compound, oral ARD-101, is in Phase 3 clinical development for the treatment of hyperphagia associated with PWS, a rare disease characterized by insatiable hunger. ARD-101 is also being studied in hypothalamic obesity. Aardvark is also developing ARD-201, a planned fixed-dose combination of ARD-101 with a DPP-4 inhibitor, and conducting two separate trials with a goal of addressing some of the limitations of currently marketed GLP-1 therapies for the treatment of obesity and obesity-related conditions. For more information, visit aardvarktherapeutics.com.  

Forward-Looking Statements 
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning: Aardvark’s business strategy, product candidates, ongoing clinical trials, planned clinical trials, likelihood of success, as well as plans and objectives of management for future operations. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to potential delays in the commencement, enrollment and completion of clinical trials; the risk that we may use our capital resources sooner than expected and that they may be insufficient to allow us to achieve our anticipated milestones; risks related to our dependence on third parties for manufacturing, shipping and clinical and preclinical trials; the risk of unfavorable clinical results; the risk that results from earlier clinical trials and preclinical studies may not necessarily be predictive of future results; and other factors described under the “Risk Factors” section of Aardvark’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 that the Company filed with the Securities and Exchange Commission on November 13, 2025. When evaluating Aardvark’s business and prospects, careful consideration should be given to these risks and uncertainties. Any forward-looking statements contained in this press release are based on the current expectations of Aardvark’s management team and speak only as of the date hereof, and Aardvark specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, unless required by law.

Contact:
Carolyn Hawley, Inizio Evoke Comms
(619) 849-5382
Carolyn.hawley@inizioevoke.com

FAQ

When will Aardvark Therapeutics (AARD) present at the Piper Sandler conference in December 2025?

Aardvark will present on Wednesday, December 3, 2025 at 8:00 a.m. ET.

When is Aardvark Therapeutics (AARD) scheduled to present at the Evercore ISI healthcare conference?

The presentation is on Thursday, December 4, 2025 at 11:15 a.m. ET.

How can investors watch Aardvark Therapeutics (AARD) presentations live in December 2025?

Live webcasts will be available via the company's investor relations website at www.aardvarktherapeutics.com.

Will Aardvark Therapeutics (AARD) make recordings of the December 2025 presentations available after the events?

Yes. Archived recordings will be posted on the investor website for about one month after each presentation.

Where on the Aardvark Therapeutics (AARD) site will the December 2025 webcast be hosted?

The webcasts and archived recordings will be accessible in the Investors section of www.aardvarktherapeutics.com.